Evidence map›Paper›PMID 41034557›Full record

ArticleCommunications biology2025

Long non-coding RNAs as a biomarker for homologous recombination deficiency and parp inhibitor sensitivity in high-grade serous ovarian cancers.

Kai Doberstein, Johannes Panther, Eric Hahnen, Lisa Richters, Philip C Schouten, Philipp Harter, Florian Heitz, Stefan Kommoss, Sebastian Berlit, Benjamin Tuschy and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kai DobersteinDepartment of Obstetrics and Gynecology, Medical Faculty Mannheim of the Heidelberg University, University Medical Centre Mannheim, Mannheim, Germany. kai.doberstein@medma.uni-heidelberg.de.ORCID http://orcid.org/0000-0002-9114-9913
Johannes PantherDepartment of Obstetrics and Gynecology, Medical Faculty Mannheim of the Heidelberg University, University Medical Centre Mannheim, Mannheim, Germany.
Eric HahnenCenter for Familial Breast and Ovarian Cancer and Center for Integrated Oncology (CIO), Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Lisa RichtersCenter for Familial Breast and Ovarian Cancer and Center for Integrated Oncology (CIO), Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0002-9233-5291
Philip C SchoutenDepartment of histopathology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, cambridge, UK.
Philipp HarterDepartment of Gynecology and Gynecologic Oncology, Evang. Kliniken Essen-Mitte, Essen, Germany.
Florian HeitzDepartment of Gynecology and Gynecologic Oncology, Evang. Kliniken Essen-Mitte, Essen, Germany.
Stefan KommossDepartment of Women's Health, Tübingen University Hospital, Tübingen, Germany.
Sebastian BerlitDepartment of Obstetrics and Gynecology, Medical Faculty Mannheim of the Heidelberg University, University Medical Centre Mannheim, Mannheim, Germany.
Benjamin TuschyDepartment of Obstetrics and Gynecology, Medical Faculty Mannheim of the Heidelberg University, University Medical Centre Mannheim, Mannheim, Germany.
Marc SütterlinDepartment of Obstetrics and Gynecology, Medical Faculty Mannheim of the Heidelberg University, University Medical Centre Mannheim, Mannheim, Germany.
Frederik MarméDepartment of Obstetrics and Gynecology, Medical Faculty Mannheim of the Heidelberg University, University Medical Centre Mannheim, Mannheim, Germany.ORCID http://orcid.org/0000-0002-6591-3367

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Homologous recombination deficiency (HRD) and sensitivity to PARP inhibitors are key determinants of therapeutic response in high-grade serous ovarian cancer (HGSC), yet predictive biomarkers beyond BRCA1/2 mutations or genomic HRD scores remain inadequate. Here, we investigate the potential of long non-coding RNAs (lncRNAs) as predictive markers of HRD and PARP inhibitor response. We identify a panel of lncRNAs that stratifies HGSC tumors by HRD status and drug sensitivity. Among these, ENSG00000272172.1 is significantly upregulated in HRD-positive tumors and is detectable in both formalin-fixed tissue and plasma, supporting its use as a minimally invasive biomarker. Functional analyses reveal that this lncRNA contributes to genome stability by modulating replication dynamics. These findings highlight a previously unrecognized role for lncRNAs in the HRD phenotype and suggest translational potential for ENSG00000272172.1 in guiding clinical decision-making.

Indexed as

Biomarkers, TumorCystadenocarcinoma, SerousHomologous RecombinationOvarian NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsRNA, Long NoncodingCell Line, TumorDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticHumansNeoplasm GradingBiomarkers, TumorPoly(ADP-ribose) Polymerase InhibitorsRNA, Long Noncoding

Identifiers

PMID41034557
PMCPMC12488886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.